机构名称：
¥ 1.0
•阿达尔塔（Adalta）的“东到西”细胞免疫疗法策略被确认为战略审查中未来管道增长和价值创造的主要驱动力，并且是公司的核心增长优先级•阿达尔塔（Adalta）将对亚洲发起人的固体癌症进行高度差异化的细胞疗法，并通过进行第一阶段I临床试验来建立价值。• This strategy provides a pathway for “Eastern” innovation to reach “Western” regulated markets and patients and aligns with a key driver of the global biopharma industry • Two new non-binding term sheets now signed following a disciplined asset selection process, bringing total products in advanced in-licensing discussions to three • Following a strategic review AdAlta's first in class antifibrotic molecule, AD-214, will continue to be advanced only via third政党交易和公司将停止内部发现研发活动，以将资源集中在“东到西”增长战略上。
Inmuron宣布Travelan®临床试验更新
主要关键词
相关文件推荐
